Two New Migraine Drugs Show Major Benefits

At the European Academy of Neurology 2025 Congress, two major studies on migraine prevention were presented. A large phase III trial revealed that eptinezumab, a migraine-specific preventive therapy, significantly reduced monthly migraine days in a predominantly Asian population, with benefits observed as early as day one and sustained through week 12. Separately, early-stage research found that the diabetes drug liraglutide, a GLP-1 receptor agonist, halved monthly migraine days in adults with chronic migraine and obesity, likely due to reduced brain fluid pressure rather than weight loss. Nearly half of liraglutide participants experienced at least a 50% reduction in headache days and reported rapid improvements in quality of life. Experts highlighted that these findings introduce intracranial pressure modulation as a promising new therapeutic target. These developments signal expanded options and improved global accessibility for effective migraine treatments.